FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022112812> ?p ?o ?g. }

• W2022112812 endingPage "1150" @default.
• W2022112812 startingPage "1141" @default.
• W2022112812 abstract "BACKGROUND Although conventional immunosuppression after liver transplantation consists of cyclosporine A (CsA), steroids, and azathioprine, recently introduced protocols entail CsA-based quadruple induction protocols or tacrolimus-based combinations. These protocols aim to reduce the rejection rate and the considerable morbidity related to the side effects of additional immunosuppressive treatment, but have not yet been analyzed regarding their long term de novo neoplastic risk. METHODS From September 1988 to May 1994, 500 liver transplantations were performed in 458 patients. The median follow-up was 50 months (range, 0.3-97 months) for all patients. Conventional triple therapy was implemented in 25 patients, CsA-based quadruple induction therapy using an antilymphocyte globulin preparation (ATG) in 190 patients, an interleukin-2 receptor antibody (BT563) in 141 patients, and tacrolimus-based dual or triple immunosuppression in 102 patients. The different protocols were evaluated in four randomized and two nonrandomized prospective trials. RESULTS De novo neoplasias were detected in 33 patients (7.2%) and were comprised of lymphomas (n = 7), skin malignancies (n = 8 lesions in 7 patients), intraepithelial neoplasias of the cervix uteri (n = 7), breast carcinoma (n = 3), lung carcinoma (n = 3), and other malignancies (n = 6). The incidence of de novo neoplasias did not differ in the different trial arms. Only a positive T-crossmatch and a low CD4+/CD8+ ratio in patients receiving CsA-based immunosuppression demonstrated a significant correlation with the development of a de novo tumor in a multivariant logistic regression analysis. CONCLUSIONS The development of de novo neoplastic diseases after liver transplantation with the use of CsA-based quadruple induction protocols or tacrolimus-based regimens for immunosuppresion was assessed over the long term. Recently introduced immunosuppressive protocols did not alter the posttransplant de novo tumor rate. Patients with a low CD4+/CD8+ ratio during CsA-based therapy or a positive T-crossmatch were identified to be at an increased risk for the development of a de novo malignancy. Cancer 1997; 80:1141-50. © 1997 American Cancer Society" @default.
• W2022112812 created "2016-06-24" @default.
• W2022112812 creator A5002162867 @default.
• W2022112812 creator A5026409990 @default.
• W2022112812 creator A5030045751 @default.
• W2022112812 creator A5031465988 @default.
• W2022112812 creator A5040837927 @default.
• W2022112812 creator A5043440234 @default.
• W2022112812 creator A5049713502 @default.
• W2022112812 creator A5060663408 @default.
• W2022112812 creator A5085085591 @default.
• W2022112812 date "1997-09-15" @default.
• W2022112812 modified "2023-10-11" @default.
• W2022112812 title "De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin" @default.
• W2022112812 cites W1873595243 @default.
• W2022112812 cites W1986819764 @default.
• W2022112812 cites W1999052450 @default.
• W2022112812 cites W2008998904 @default.
• W2022112812 cites W2011176464 @default.
• W2022112812 cites W2011593947 @default.
• W2022112812 cites W2012302408 @default.
• W2022112812 cites W2014937663 @default.
• W2022112812 cites W2025451399 @default.
• W2022112812 cites W2031832264 @default.
• W2022112812 cites W2034334866 @default.
• W2022112812 cites W2042849224 @default.
• W2022112812 cites W2046830658 @default.
• W2022112812 cites W2050069240 @default.
• W2022112812 cites W2062593700 @default.
• W2022112812 cites W2066898716 @default.
• W2022112812 cites W2089391684 @default.
• W2022112812 cites W2129465528 @default.
• W2022112812 cites W2141029949 @default.
• W2022112812 cites W4236461081 @default.
• W2022112812 cites W4241592298 @default.
• W2022112812 cites W4253784048 @default.
• W2022112812 doi "https://doi.org/10.1002/(sici)1097-0142(19970915)80:6<1141::aid-cncr18>3.0.co;2-8" @default.
• W2022112812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9305716" @default.
• W2022112812 hasPublicationYear "1997" @default.
• W2022112812 type Work @default.
• W2022112812 sameAs 2022112812 @default.
• W2022112812 citedByCount "175" @default.
• W2022112812 countsByYear W20221128122012 @default.
• W2022112812 countsByYear W20221128122013 @default.
• W2022112812 countsByYear W20221128122014 @default.
• W2022112812 countsByYear W20221128122015 @default.
• W2022112812 countsByYear W20221128122016 @default.
• W2022112812 countsByYear W20221128122017 @default.
• W2022112812 countsByYear W20221128122018 @default.
• W2022112812 countsByYear W20221128122019 @default.
• W2022112812 countsByYear W20221128122020 @default.
• W2022112812 countsByYear W20221128122021 @default.
• W2022112812 countsByYear W20221128122022 @default.
• W2022112812 crossrefType "journal-article" @default.
• W2022112812 hasAuthorship W2022112812A5002162867 @default.
• W2022112812 hasAuthorship W2022112812A5026409990 @default.
• W2022112812 hasAuthorship W2022112812A5030045751 @default.
• W2022112812 hasAuthorship W2022112812A5031465988 @default.
• W2022112812 hasAuthorship W2022112812A5040837927 @default.
• W2022112812 hasAuthorship W2022112812A5043440234 @default.
• W2022112812 hasAuthorship W2022112812A5049713502 @default.
• W2022112812 hasAuthorship W2022112812A5060663408 @default.
• W2022112812 hasAuthorship W2022112812A5085085591 @default.
• W2022112812 hasBestOaLocation W20221128121 @default.
• W2022112812 hasConcept C126322002 @default.
• W2022112812 hasConcept C203014093 @default.
• W2022112812 hasConcept C2776760755 @default.
• W2022112812 hasConcept C2779134260 @default.
• W2022112812 hasConcept C2779609443 @default.
• W2022112812 hasConcept C2780252810 @default.
• W2022112812 hasConcept C2909675724 @default.
• W2022112812 hasConcept C2911091166 @default.
• W2022112812 hasConcept C71924100 @default.
• W2022112812 hasConcept C90924648 @default.
• W2022112812 hasConceptScore W2022112812C126322002 @default.
• W2022112812 hasConceptScore W2022112812C203014093 @default.
• W2022112812 hasConceptScore W2022112812C2776760755 @default.
• W2022112812 hasConceptScore W2022112812C2779134260 @default.
• W2022112812 hasConceptScore W2022112812C2779609443 @default.
• W2022112812 hasConceptScore W2022112812C2780252810 @default.
• W2022112812 hasConceptScore W2022112812C2909675724 @default.
• W2022112812 hasConceptScore W2022112812C2911091166 @default.
• W2022112812 hasConceptScore W2022112812C71924100 @default.
• W2022112812 hasConceptScore W2022112812C90924648 @default.
• W2022112812 hasIssue "6" @default.
• W2022112812 hasLocation W20221128121 @default.
• W2022112812 hasLocation W20221128122 @default.
• W2022112812 hasOpenAccess W2022112812 @default.
• W2022112812 hasPrimaryLocation W20221128121 @default.
• W2022112812 hasRelatedWork W1705018154 @default.
• W2022112812 hasRelatedWork W2003755555 @default.
• W2022112812 hasRelatedWork W2011454096 @default.
• W2022112812 hasRelatedWork W2039925961 @default.
• W2022112812 hasRelatedWork W2056167279 @default.
• W2022112812 hasRelatedWork W2081190402 @default.
• W2022112812 hasRelatedWork W2170708782 @default.
• W2022112812 hasRelatedWork W2397346604 @default.
• W2022112812 hasRelatedWork W4230961654 @default.

• next